Lead Product(s): AP-301
Therapeutic Area: Nephrology Product Name: AP-301
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Quan Capital
Deal Size: $60 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 09, 2021
Alebund Pharmaceuticals lead product, AP-301, is a best-in-class potential in the treatment of hyperphosphatemia.